全文获取类型
收费全文 | 2338篇 |
免费 | 123篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 94篇 |
妇产科学 | 63篇 |
基础医学 | 251篇 |
口腔科学 | 54篇 |
临床医学 | 189篇 |
内科学 | 482篇 |
皮肤病学 | 22篇 |
神经病学 | 204篇 |
特种医学 | 213篇 |
外科学 | 329篇 |
综合类 | 31篇 |
预防医学 | 128篇 |
眼科学 | 74篇 |
药学 | 126篇 |
中国医学 | 8篇 |
肿瘤学 | 200篇 |
出版年
2023年 | 16篇 |
2022年 | 24篇 |
2021年 | 52篇 |
2020年 | 26篇 |
2019年 | 34篇 |
2018年 | 45篇 |
2017年 | 29篇 |
2016年 | 42篇 |
2015年 | 44篇 |
2014年 | 56篇 |
2013年 | 79篇 |
2012年 | 103篇 |
2011年 | 115篇 |
2010年 | 86篇 |
2009年 | 99篇 |
2008年 | 105篇 |
2007年 | 109篇 |
2006年 | 110篇 |
2005年 | 108篇 |
2004年 | 89篇 |
2003年 | 86篇 |
2002年 | 67篇 |
2001年 | 58篇 |
2000年 | 65篇 |
1999年 | 66篇 |
1998年 | 41篇 |
1997年 | 49篇 |
1996年 | 58篇 |
1995年 | 44篇 |
1994年 | 36篇 |
1993年 | 41篇 |
1992年 | 34篇 |
1991年 | 36篇 |
1990年 | 42篇 |
1989年 | 43篇 |
1988年 | 41篇 |
1987年 | 42篇 |
1986年 | 37篇 |
1985年 | 31篇 |
1984年 | 26篇 |
1983年 | 16篇 |
1982年 | 23篇 |
1981年 | 10篇 |
1980年 | 18篇 |
1979年 | 14篇 |
1977年 | 12篇 |
1976年 | 9篇 |
1975年 | 10篇 |
1973年 | 10篇 |
1971年 | 6篇 |
排序方式: 共有2477条查询结果,搜索用时 15 毫秒
51.
Higher fat and energy intakes confer a survival advantage in cystic fibrosis (CF). There is a need to develop effective nutrition programmes that ensure optimal energy intake in CF.
A cross-sectional measurement of clinical characteristics and energy and fat intakes in patients attending the CF outpatients clinic of the John Hunter Hospital, Newcastle was undertaken. Twenty-nine subjects, mean age 12 years (range 4.3–20.2), completed weighed food records to determine the contribution of fat to the percentage of the recommended energy intake obtained and to document use of pancreatic enzyme replacement therapy.
Diets with a high percentage of energy derived from fat did not guarantee that individuals with CF met their energy requirements. Subjects with total fat intakes of 100 g per day or greater, however, achieved in excess of 110% recommended daily intake (RDI) for energy. Up to 47% of subjects consumed more pancreatic enzyme replacement capsules than shown to give maximum effectiveness.
Setting a 100 g daily fat target is a realistic way of ensuring high energy intakes in CF. Fat ready reckoners would identify the fat content of food and prescribe specific numbers of pancreatic enzyme replacement capsules to be consumed with each meal or food item. 相似文献
Methodology:
A cross-sectional measurement of clinical characteristics and energy and fat intakes in patients attending the CF outpatients clinic of the John Hunter Hospital, Newcastle was undertaken. Twenty-nine subjects, mean age 12 years (range 4.3–20.2), completed weighed food records to determine the contribution of fat to the percentage of the recommended energy intake obtained and to document use of pancreatic enzyme replacement therapy.
Results:
Diets with a high percentage of energy derived from fat did not guarantee that individuals with CF met their energy requirements. Subjects with total fat intakes of 100 g per day or greater, however, achieved in excess of 110% recommended daily intake (RDI) for energy. Up to 47% of subjects consumed more pancreatic enzyme replacement capsules than shown to give maximum effectiveness.
Conclusion:
Setting a 100 g daily fat target is a realistic way of ensuring high energy intakes in CF. Fat ready reckoners would identify the fat content of food and prescribe specific numbers of pancreatic enzyme replacement capsules to be consumed with each meal or food item. 相似文献
52.
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. 总被引:3,自引:0,他引:3
S Mariani M Muraro F Pantaleoni F Fiore B Nuschak S Peola M Foglietta A Palumbo M Coscia B Castella B Bruno R Bertieri L Boano M Boccadoro M Massaia 《Leukemia》2005,19(4):664-670
The aim of this study was to investigate the in vitro immunomodulatory effects of zoledronic acid (Zol) on peripheral blood Vgamma9/Vdelta2 (gammadelta) T cells of normal donors and multiple myeloma (MM) patients. gammadelta T cells were stimulated with Zol and low doses of interleukin-2 (IL-2), and then analyzed for proliferation, cytokine production, and generation of effector activity against myeloma cell lines and primary myeloma cells. Proliferation of gammadelta T cells was observed in 100% of normal donors and 50% of MM patients. gammadelta T cells produced IFN-gamma, surface mobilized the CD107a and CD107b antigens, and exerted direct cell-to-cell antimyeloma activity irrespective of the ability to proliferate to Zol and IL-2. The memory phenotype was predominant in the MM gammadelta T cells that proliferated in response to Zol (responders), whereas effector cells were predominant in those that did not (nonresponders). Zol induced antimyeloma activity through the monocyte-dependent activation of gammadelta T cells and by enhancing the immunosensitivity of myeloma cells to gammadelta T cells. Mevastatin, a specific inhibitor of hydroxy-methylglutaryl-CoA reductase, completely abrogated this antimyeloma activity. 相似文献
53.
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. 总被引:5,自引:0,他引:5
John P Leonard Morton Coleman Jamie Ketas Michelle Ashe Jennifer M Fiore Richard R Furman Ruben Niesvizky Tsiporah Shore Amy Chadburn Heather Horne Jacqueline Kovacs Cliff L Ding William A Wegener Ivan D Horak David M Goldenberg 《Journal of clinical oncology》2005,23(22):5044-5051
PURPOSE: To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Twenty-three patients with recurrent B-cell lymphoma received anti-CD22 epratuzumab 360 mg/m(2) and anti-CD20 rituximab 375 mg/m(2) monoclonal antibodies weekly for four doses each. Sixteen patients had indolent histologies (15 with follicular lymphoma) and seven had aggressive NHL (all diffuse large B-cell lymphoma [DLBCL]). Indolent patients had received a median of one (range, one to six) prior treatment, with 31% refractory to their last therapy and 81% with high-risk Follicular Lymphoma International Prognostic Index scores. Patients with DLBCL had a median of three (range, one to eight) prior regimens (14% resistant to last treatment) and 71% had high intermediate-risk or high-risk International Prognostic Index scores. All patients were rituximab na?ve. RESULTS: Treatment was well tolerated, with toxicities principally infusion-related and predominantly grade 1 or 2. Ten (67%) patients with follicular NHL achieved an objective response (OR), including nine of 15 (60%) with complete responses (CRs and unconfirmed CRs). Four of six assessable patients (67%) with DLBCL achieved an OR, including three (50%) CRs. Median time to progression for all indolent NHL patients was 17.8 months. CONCLUSION: The full-dose combination of epratuzumab with rituximab was well tolerated and had significant clinical activity in NHL, suggesting that this combination should be tested in comparison with single-agent treatment. 相似文献
54.
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. 总被引:4,自引:0,他引:4
John P Leonard Morton Coleman Lale Kostakoglu Amy Chadburn Ethel Cesarman Richard R Furman Michael W Schuster Ruben Niesvizky Daniel Muss Jennifer Fiore Stewart Kroll George Tidmarsh Shankar Vallabhajosula Stanley J Goldsmith 《Journal of clinical oncology》2005,23(24):5696-5704
PURPOSE: To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma. PATIENTS AND METHODS: Thirty-five patients received an abbreviated course (three cycles) of fludarabine followed 6 to 8 weeks later by tositumomab and iodine I 131 tositumomab. RESULTS: After fludarabine, 31 (89%) of 35 patients responded, with three (9%) of 31 patients achieving a complete response (CR). After the full regimen of fludarabine and iodine I 131 tositumomab, all 35 patients responded; 30 (86%) of 35 patients achieved CR, and five (14%) of 35 achieved partial response. After a median follow-up of 58 months, the median progression-free survival (PFS) had not been reached (95% CI, 27 months to not reached), but it will be at least 48 months. The 5-year estimated PFS rate is 60%. Baseline Follicular Lymphoma International Prognostic Index (FLIPI) was significantly associated (P = .003) with PFS. Five of six patients with more than 25% bone marrow involvement at baseline achieved adequate bone marrow cytoreduction to receive standard-dose iodine I 131 tositumomab. Ten (77%) of 13 patients with baseline bone marrow Bcl-2 positivity demonstrated molecular remissions at month 12. Toxicities were manageable and principally hematologic. Two (6%) of 35 patients developed human antimurine antibodies (HAMA) after RIT. CONCLUSION: Use of abbreviated fludarabine before iodine I 131 tositumomab can reduce bone marrow involvement, when needed, to allow the use of RIT and can suppress HAMA responses. This sequential treatment regimen is highly effective as front-line therapy for follicular lymphoma, particularly for low- or intermediate-risk FLIPI patients. 相似文献
55.
56.
57.
Pretreatment assessment in patients with cancer of the gastroesophageal junction involves the evaluation of physiological status and tumor stage. Nutritional status is a prognostic and predictor factor of response to treatment; assessment involves the calculation of weight loss and the determination of serum albumin. Renal, cardiac, and pulmonary functions are evaluated (urea, creatinine, calculation of clearance, liver function tests, electrocardiogram, pulmonary function). The performance status (Karnofsky or WHO) is an important prognostic factor. The assessment of tumor stage involves the digestive endoscopy and endoscopic ultrasonography, CT thoraco-abdomino-pelvic injection, and PET-FDG. Laparoscopy is performed only when peritoneal involvement is suspected. 相似文献
58.
59.
60.